Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization
- PMID: 38165181
- PMCID: PMC10754187
- DOI: 10.5811/westjem.60511
Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization
Abstract
Introduction: Recent studies have demonstrated the promise of emergency department (ED)-initiated buprenorphine/naloxone (bup/nx) for improving 30-day retention in outpatient addiction care programs for patients with opioid use disorder (OUD). We investigated whether ED-initiated bup/nx for OUD also impacts repeat ED utilization.
Methods: We performed a retrospective chart review of ED patients discharged with a primary diagnosis of OUD from July 2019-December 2020. Characteristics considered included age, gender, race, insurance status, domicile status, presence of comorbid Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis, presenting chief complaint, and provision of a bup/nx prescription and/or naloxone kit. Primary outcomes included repeat ED visit (opioid or non-opioid related) within 30 days, 90 days, and one year. Statistical analyses included bivariate comparison and Poisson regression.
Results: Of 169 participants, the majority were male (67.5%), White (82.8%), uninsured (72.2%), and in opioid withdrawal and/or requesting "detox" (75.7%). Ninety-one (53.8%) received ED-initiated bup/nx, which was independent of age, gender, race, insurance status, presence of comorbid DSM-5 diagnosis, or domicile status. Naloxone was more likely to be provided to patients who received bup/nx (97.8% vs 26.9%; P < 0.001), and bup/nx was more likely to be given to patients who presented with opioid withdrawal and/or requested "detox" (63.3% vs 36.7%; P < 0.001). Bup/nx provision was associated with decreased ED utilization for opioid-related visits at 30 days (P = 0.04). Homelessness and lack of insurance were associated with increased ED utilization for non-opioid-related visits at 90 days (P = 0.008 and P = 0.005, respectively), and again at one year for homelessness (P < 0.001). When controlling for age and domicile status, the adjusted incidence rate ratio for overall ED visits was 0.56 (95% confidence interval [CI] 0.33-0.96) at 30 days, 0.43 (95% CI 0.27-0.69) at 90 days, and 0.60 (95% CI 0.39-0.92) at one year, favoring bup/nx provision.
Conclusion: Initiation of bup/nx in the ED setting was associated with decreased subsequent ED utilization. Socioeconomic factors, specifically health insurance and domicile status, significantly impacted non-opioid-related ED reuse. These findings demonstrate the ED's potential as an initiation point for bup/nx and highlight the importance of considering the social risk and social need for OUD patients.
Conflict of interest statement
Conflicts of Interest: By the
Similar articles
-
Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.Am J Drug Alcohol Abuse. 2022 Mar 4;48(2):217-225. doi: 10.1080/00952990.2021.1981358. Epub 2021 Nov 15. Am J Drug Alcohol Abuse. 2022. PMID: 34780312
-
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1(Suppl 1):S22-32. doi: 10.1097/QAI.0b013e318209751e. J Acquir Immune Defic Syndr. 2011. PMID: 21317590 Free PMC article. Clinical Trial.
-
Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7. Pain. 2013. PMID: 23707283 Free PMC article.
-
Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.J Addict Nurs. 2019 Oct/Dec;30(4):254-260. doi: 10.1097/JAN.0000000000000308. J Addict Nurs. 2019. PMID: 31800516
-
Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.Am J Emerg Med. 2019 Jan;37(1):143-150. doi: 10.1016/j.ajem.2018.10.013. Epub 2018 Oct 11. Am J Emerg Med. 2019. PMID: 30355476 Review.
References
-
- Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available at: https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. Published December 2022. Accessed March 13, 2023.
-
- Spencer MR, Miniño AM, Warner M. Drug overdose deaths in the United States, 2001–2021. NCHS Data Brief, no 457. Hyattsville, MD: National Center for Health Statistics. 2022. Available at: https://www.cdc.gov/nchs/data/databriefs/db457.pdf. Accessed March 13, 2023.
-
- U.S. opioid dispensing rate maps . Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/drugoverdose/rxrate-maps/index.html. Published November 10, 2021. Accessed March 13, 2023.
-
- Annual 2021 Report Jefferson County Coroner/Medical Examiner’s Office . Available at: https://www.jccal.org/Sites/Jefferson_County/Documents/Coroner_Medical%2.... Accessed March 13, 2023.